Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy

NCT07289763 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

75

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Membranous Nephropathy

Interventions

DRUG: SHR-2173 injection
DRUG: SHR-2173 injection
DRUG: SHR-2173 injection

Sponsor

Guangdong Hengrui Pharmaceutical Co., Ltd